3,895 results match your criteria American journal of nephrology[Journal]


Cardiovascular Benefits of a Diet Enriched in Fruits and Vegetables.

Am J Nephrol 2019 Apr 17;49(6):435-437. Epub 2019 Apr 17.

Distinguished Scientist-in-Residence, Department of Health Studies, College of Arts and Sciences, American University, Washington, District of Columbia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500044DOI Listing

Kidney Disease Awareness and Knowledge among Survivors ofAcute Kidney Injury.

Am J Nephrol 2019 Apr 17;49(6):449-459. Epub 2019 Apr 17.

Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Center for Kidney Diseases (VCKD) and Integrated Program for AKI Research (VIP-AKI), Nashville, Tennessee, USA.

Background: Acute kidney injury (AKI) survivors are at risk for chronic kidney disease, recurrent AKI, and cardiovascular disease. The transition from hospital to ambulatory care is an opportunity to reduce these sequelae by launching self-care plans through effective patient education. How well AKI survivors are informationally prepared to apply kidney-specific self-care is unknown. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499862
Publisher Site
http://dx.doi.org/10.1159/000499862DOI Listing
April 2019
3 Reads

Fruit and Vegetable Treatment of Chronic Kidney Disease-Related Metabolic Acidosis Reduces Cardiovascular Risk Better than Sodium Bicarbonate.

Am J Nephrol 2019 Apr 17;49(6):438-448. Epub 2019 Apr 17.

Department of Internal Medicine, Texas A&M Health Sciences Center College of Medicine, Dallas, Texas, USA,

Background: Current guidelines recommend treatment of metabolic acidosis in chronic kidney disease (CKD) with sodium-based alkali. We tested the hypothesis that treatment with base-producing fruits and vegetables (F + V) better improves cardiovascular disease (CVD) risk indicators than oral sodium bicarbonate (NaHCO3).

Methods: We randomized 108 macroalbuminuric, matched, nondiabetic CKD patients with metabolic acidosis to F + V (n = 36) in amounts to reduce dietary acid by half, oral NaHCO3 (HCO3, n = 36) 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500042DOI Listing
April 2019
1 Read
2.669 Impact Factor

Histopathologic Features that Predict Transplant Glomerulopathy Progression in a Chinese Cohort.

Am J Nephrol 2019 Apr 16;49(6):425-434. Epub 2019 Apr 16.

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Medical School of Nanjing University, Nanjing, China,

Background: Transplant glomerulopathy (TG) represents a major cause of long-term allograft failure and is the leading cause of overall post-transplant proteinuria. The extent to which histopathologic features predicts prognostication is uncertain.

Methods: A single-center retrospective cohort with biopsy-proven TG was investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500043DOI Listing
April 2019
1 Read

Challenges in Managing Pregnancy in Underserved Women with Chronic Kidney Disease.

Am J Nephrol 2019 Apr 12;49(5):386-396. Epub 2019 Apr 12.

Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, University of Guadalajara Health Sciences Center, Guadalajara, Mexico,

Background: Chronic kidney disease (CKD) is a global public health problem and is linked to adverse outcomes during pregnancy; the high prevalence of CKD (3-6%) in women of childbearing age is of particular relevance in emerging countries where CKD prevalence is higher and resources are limited. Although CKD is a public health problem in Mexico, there is scant information on outcomes in pregnant CKD women in this country. We report maternal-fetal outcomes in a prospective cohort of poor, CKD pregnant women, and compare results with those of pregnant women without CKD. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499964
Publisher Site
http://dx.doi.org/10.1159/000499964DOI Listing
April 2019
2 Reads

Failure in Physiologic Flexibility: Adverse Pregnancy Outcomes in Women with Reduced Renal Reserve.

Am J Nephrol 2019 Apr 12;49(5):397-399. Epub 2019 Apr 12.

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499966DOI Listing

The Spectrum of Adverse Pregnancy Outcomes Based on Kidney Disease Diagnoses: A 20-Year Population Study.

Am J Nephrol 2019 Apr 12;49(5):400-409. Epub 2019 Apr 12.

Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal Adelaide Hospital, Adelaide, South Australia, Australia,

Background And Objectives: Kidney disorders in pregnancy may be under-recognized and have variable impact on outcomes depending on diagnosis. Population-level data are limited, particularly for Australia, and comparison of impact of different kidney disorders on pregnancy has rarely been assessed. This study examined the prevalence and outcomes of varied kidney disorders using population-level perinatal data from a large cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499965DOI Listing
April 2019
1 Read

Treating Systemic Klotho Deficiency.

Am J Nephrol 2019 Apr 12;49(5):410-412. Epub 2019 Apr 12.

Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499864DOI Listing

Therapeutic Challenge of Minicircle Vector Encoding Klotho in Animal Model.

Am J Nephrol 2019 Apr 12;49(5):413-424. Epub 2019 Apr 12.

Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea,

Background: Klotho treatment is a promising approach against kidney injury, but its clinical application is still undetermined. We developed a novel strategy to allow self-production of Klotho protein, using minicircle (MC) technology, and evaluated its feasibility in therapeutic Klotho delivery.

Methods: We engineered MC vectors to carry cassette sequences of Klotho and verified the self-production of Klotho protein from in HEK293T cells. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499863
Publisher Site
http://dx.doi.org/10.1159/000499863DOI Listing
April 2019
1 Read

Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Am J Nephrol 2019 Apr 9;49(5):377-385. Epub 2019 Apr 9.

Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, Maryland, USA,

Background: In adults with primary focal segmental glomerulosclerosis (FSGS), daily prednisone may induce complete remissions (CR) and partial remissions (PR), but relapses are frequent and adverse events are common.

Methods: We carried out 2 open-label, uncontrolled trials to explore the efficacy and tolerability of pulse oral dexamethasone as an alternative to daily prednisone. We enrolled adult patients with proteinuria > 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497064DOI Listing
April 2019
1 Read

Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.

Am J Nephrol 2019 Apr 2;49(5):359-367. Epub 2019 Apr 2.

Providence Medical Research Center, Providence Health Care, Spokane, Washington, USA.

Rationale And Objective: In the Systolic Blood Pressure Intervention Trial, the possible relationships between acute kidney injury (AKI) and risk of major cardiovascular events and death are not known.

Study Design: Post hoc analysis of a multicenter, randomized, controlled, open-label clinical trial.

Setting And Participants: Hypertensive adults without diabetes who were ≥50 years of age with prior cardiovascular disease, chronic kidney disease (CKD), 10-year Framingham risk score > 15%, or age > 75 years were assigned to a systolic blood pressure target of < 120 mm Hg (intensive) or < 140 mm Hg (standard). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499574DOI Listing
April 2019
4 Reads

Blood Pressure Control, Acute Kidney Injury, and Cardiovascular Events: Separating the Chaff from the Wheat.

Am J Nephrol 2019 Apr 2;49(5):356-358. Epub 2019 Apr 2.

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499575DOI Listing
April 2019
2 Reads

Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease.

Am J Nephrol 2019 Apr 2;49(5):346-355. Epub 2019 Apr 2.

Department of Medicine, University of California, San Diego, California, USA.

Background: Kidney tubulointerstitial fibrosis on biopsy is a strong predictor of chronic kidney disease (CKD) progression, and CKD is associated with elevated risk of cardiovascular disease (CVD). Tubular health is poorly quantified by traditional kidney function measures, including estimated glomerular filtration rate (eGFR) and albuminuria. We hypothesized that urinary biomarkers of tubular injury, inflammation, and repair would be associated with higher risk of CVD and mortality in persons with CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499531DOI Listing
April 2019
1 Read

Extracting Meaning of Tubular Injury Molecules: Implications for Cardiorenal Health.

Am J Nephrol 2019 Apr 2;49(5):343-345. Epub 2019 Apr 2.

Université de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499533DOI Listing
April 2019
1 Read

Modeled Daily Ingested, Absorbed and Bound Phosphorus: New Measures of Mineral Balance in Hemodialysis Patients.

Am J Nephrol 2019 Apr 2;49(5):368-376. Epub 2019 Apr 2.

Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois, USA,

Background: Control of predialysis serum phosphorus in hemodialysis patients is challenging. We explored the utility of a novel kinetic phosphorus modeling program.

Methods: As part of a quality assurance program, urea kinetic modeling results were combined with those from phosphorus kinetic modeling to compute modeled daily ingested phosphorus (DIP) and components making up this metric, including absorbed, bound, and nonabsorbed, nonbound phosphorus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499438DOI Listing
April 2019
1 Read

Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.

Am J Nephrol 2019 28;49(4):331-342. Epub 2019 Mar 28.

Departments of Physiology and of Medicine and Hypertension and Renal Center of Excellence, Tulane University School of Medicine, New Orleans, Louisiana, USA.

Background: Hypertension and renal injury are common complications of type 2 diabetes mellitus (T2DM). Hyperglycemia stimulates renal proximal tubular angiotensinogen (AGT) expression via elevated oxidative stress contributing to the development of high blood pressure and diabetic nephropathy. The sodium glucose cotransporter 2 (SGLT2) in proximal tubules is responsible for the majority of glucose reabsorption by renal tubules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475450PMC

Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease.

Am J Nephrol 2019 28;49(4):328-330. Epub 2019 Mar 28.

Division of Nephrology, University of Toronto, Toronto, Ontario, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499598DOI Listing

Comparison of 24-hour and Office Pulse Wave Velocity for Prediction of Mortality in Hemodialysis Patients.

Am J Nephrol 2019 27;49(4):317-327. Epub 2019 Mar 27.

Department of Nephrology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.

Background: Mortality in hemodialysis patients still remains unacceptably high. Enhanced arterial stiffness is a known cardiovascular risk factor, and pulse wave velocity (PWV) has proven to be a valid parameter to quantify risk. Recent studies showed controversial results regarding the prognostic significance of PWV for mortality in hemodialysis patients, which may be due to methodological issues, such as assessment of PWV in the office setting (Office-PWV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499532DOI Listing

Systolic Blood Pressure Intervention Trial and Statins, a Story of Statistical Interaction.

Am J Nephrol 2019 27;49(4):294-296. Epub 2019 Mar 27.

Indiana University School of Medicine, Indianapolis, Indiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499189DOI Listing

Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis.

Am J Nephrol 2019 27;49(4):297-306. Epub 2019 Mar 27.

Katz Family and Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA,

Background: Management of chronic kidney disease (CKD) patients includes efforts directed toward modifying traditional cardiovascular risk factors. Such efforts include optimal management of hypertension together with the initiation of statin therapy.

Methods: In this observational study, we determine the modifying effect of statins on the relationship of systolic blood pressure (SBP) goal with mortality and other outcomes in patients with CKD participating in a clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499188DOI Listing

Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.

Am J Nephrol 2019 27;49(4):307-316. Epub 2019 Mar 27.

Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, China,

Background: Aberrant O-glycosylation IgA1 production is a major factor in the pathogenesis of IgA nephropathy, but the underlying mechanism is still unclear. IgA1 glycosylation modification is in Golgi, and downregulation of the Golgi peripheral membrane protein Golgi matrix protein 130 (GM130) could lead to glycosylation deficiency. In this study, we aimed to explore the role of GM130 in glycosylate deficiency IgA1 (Gd-IgA1) production. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499110DOI Listing
March 2019
6 Reads

Aiming Too Low: Reevaluation of Target Concentrations of Serum 25-Hydroxyvitamin D in Secondary Hyperparathyroidism.

Am J Nephrol 2019 15;49(4):281-283. Epub 2019 Mar 15.

Departments of Medicine and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499160
Publisher Site
http://dx.doi.org/10.1159/000499160DOI Listing
March 2019
8 Reads

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.

Am J Nephrol 2019 15;49(4):284-293. Epub 2019 Mar 15.

Renal Division, OPKO Health, Inc., Miami, Florida, USA.

Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499187
Publisher Site
http://dx.doi.org/10.1159/000499187DOI Listing
March 2019
8 Reads

Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.

Am J Nephrol 2019 8;49(4):271-280. Epub 2019 Mar 8.

Research & Development, Pharmaceuticals, Bayer AG, Wuppertal, Germany.

Background: Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and safety of molidustat were recently evaluated in three 16-week phase 2b studies. Here, we report the results of two long-term extension studies of molidustat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499111DOI Listing
March 2019
1 Read

Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.

Am J Nephrol 2019 28;49(3):225-232. Epub 2019 Feb 28.

Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.

Background: Mineral and bone disorder (MBD) is common in patients with chronic kidney disease (CKD), and is associated with risk of fractures, cardiovascular disease, and death. Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring CKD-MBD biochemical markers, including parathyroid hormone (PTH), phosphorus, 25-hydroxyvitamin D (25D), calcium, and alkaline phosphatase (ALP), in patients with moderate-to-severe CKD.

Methods: To determine guideline adherence, we used administrative claims records from the 20% sample of Medicare beneficiaries with Parts A, B, and D coverage, 2007 to 2015, and identified cohorts of patients with nondialysis stage 3, 4, or 5 CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497477DOI Listing
February 2019
2 Reads

Genotype-Clinical Correlations in Polycystic Kidney Disease with No Apparent Family History.

Am J Nephrol 2019 28;49(3):233-240. Epub 2019 Feb 28.

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Background: Genetic characteristics of polycystic kidney disease (PKD) patients without apparent family history were reported to be different from those with a positive family history. However, the clinical course of PKD patients with no apparent family history is not well documented in the literature.

Methods: We evaluated the relationship between genotype and the clinical course of 62 PKD patients with no apparent family history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497444DOI Listing
February 2019
1 Read

Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study.

Am J Nephrol 2019 28;49(4):263-270. Epub 2019 Feb 28.

Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.

Background: Long-term patterns of fibroblast growth factor 23 (FGF23) are poorly characterized among dialysis patients.

Objectives: To identify different FGF23 trajectories and determine clinical factors that predict distinct FGF23 trajectories and whether FGF23 trajectories differ in regard to their associations with all-cause mortality among prevalent hemodialysis patients.

Methods: The HEMO study was a randomized multicenter study evaluating the effects of high-dose vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469501PMC
February 2019
4 Reads

Temporal Trends in Incident Mortality in Dialysis Patients: Focus on Sex and Racial Disparities.

Am J Nephrol 2019 28;49(3):241-253. Epub 2019 Feb 28.

Division of Nephrology Kidney CARE Program, University of Cincinnati, Cincinnati, Ohio, USA.

Background: Racial minorities and women constitute substantial portions of the incident and prevalent end-stage renal disease (ESRD) population in the United States. Although ESRD is characterized by high mortality, temporal trends, and race and sex differences in mortality have not been studied.

Methods: We evaluated 944,650 adult patients who initiated dialysis between January 1, 2005 and December 31, 2014, using the United States Renal Data System, for sex-related and race-related trends in mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497446DOI Listing
February 2019
2 Reads

Burden, Access, and Disparities in Kidney Disease.

Am J Nephrol 2019 1;49(3):254-262. Epub 2019 Mar 1.

Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt.

Kidney disease is a global public health problem, affecting over 750 million persons worldwide. The burden of kidney disease varies substantially across the world. In many settings, rates of kidney disease and the provision of its care are defined by socioeconomic, cultural, and political factors leading to significant disparities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497540DOI Listing
March 2019
1 Read

Genome-Wide Association Scan of Serum Urea in European Populations Identifies Two Novel Loci.

Am J Nephrol 2019 26;49(3):193-202. Epub 2019 Feb 26.

Lifelines Cohort Study and Biobank, Groningen, The Netherlands.

Background: Serum urea level is a heritable trait, commonly used as a diagnostic marker for kidney function. Genome-wide association studies (GWAS) in East-Asian populations identified a number of genetic loci related to serum urea, however there is a paucity of data for European populations.

Methods: We performed a two-stage meta-analysis of GWASs on serum urea in 13,312 participants, with independent replication in 7,379 participants of European ancestry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496930DOI Listing
February 2019

Renal Outcomes of Pregnant Patients with Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis.

Am J Nephrol 2019 26;49(3):214-224. Epub 2019 Feb 26.

Department of Nephropathy, Huashan Hospital, Fudan University, Shanghai, China,

Background: Is the prognosis of immunoglobulin A nephropathy (IgAN) influenced by pregnancy and delivery? The answer to this question still remains to be a controversial topic. Here, we undertook a systematic review and meta-analysis to obtain the overall estimate of potential effect of IgAN and pregnancy on each other.

Methods: We systematically searched MEDLINE, EMBASE, Chinese Biological Medicine and Cochrane for cohort and case-control studies; a total of 1,378 articles were reviewed and 9 studies were included in the end. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496410DOI Listing
February 2019
4 Reads

Pregnancy in IgA Nephropathy: An Effect on Renal Outcome?

Am J Nephrol 2019 26;49(3):212-213. Epub 2019 Feb 26.

Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495882DOI Listing
February 2019
3 Reads

Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.

Am J Nephrol 2019 26;49(3):203-211. Epub 2019 Feb 26.

Department of Nephrology and Hypertension, Internal Medicine IV, Saarland University Medical Center, Homburg, Germany.

Background: Various epidemiological studies linked high fibroblast growth factor 23 (FGF23) levels with cardiovascular events in chronic kidney disease (CKD). It remains enigmatic whether high FGF23 exerts adverse cardiovascular effects, or whether it reflects detrimental effects of residual confounders. Earlier studies adjusted for CKD-mineral bone disease (CKD-MBD) regulators of FGF23 rather than for recently discovered non-CKD-MBD regulators, among which iron deficiency and heart failure are of particular importance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497125DOI Listing
February 2019
1 Read

End-Stage Kidney Diseases in Immigrant Groups: A Nationwide Cohort Study in Sweden.

Am J Nephrol 2019 1;49(3):186-192. Epub 2019 Feb 1.

Center for Primary Health Care Research, Lund University, Malmö, Sweden.

Background: Our aim was to study the association between the country of birth and incident end-stage kidney disease (ESKD) in several immigrant groups in Sweden, using individuals born in Sweden or with Swedish-born parents as referents.

Methods: A cohort study of first- and second-generation immigrants residing in Sweden between January 1, 1998 and December 31, 2012 was performed. Outcomes were defined as having at least one registered diagnosis of ESKD in the National Patient Register. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497063
Publisher Site
http://dx.doi.org/10.1159/000497063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433394PMC
February 2019
4 Reads

A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.

Am J Nephrol 2019 30;49(2):165-174. Epub 2019 Jan 30.

Fukuoka Renal Clinic, Fukuoka, Japan.

Background: Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that mimics adaptive responses to hypoxic conditions and may provide a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy, safety, and maintenance dose of enarodustat in anemic patients with CKD not on dialysis.

Methods: Erythropoiesis-stimulating agent (ESA) naïve patients (correction group) and patients on a stable dose of ESA (conversion group) were randomized to receive 2, 4, or 6 mg of enarodustat or placebo once daily for 6 weeks in a double-blind manner (Period 1) followed by 24 weeks of open enarodustat treatment to maintain their hemoglobin (Hb) levels within a target range of 10. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/496929
Publisher Site
http://dx.doi.org/10.1159/000496929DOI Listing
January 2019
2 Reads

Postoperative Acute Kidney Injury: Focus on Renal Recovery Definitions, Kidney Disease Progression and Survival.

Am J Nephrol 2019 30;49(3):175-185. Epub 2019 Jan 30.

Faculty of Medicine, University of Iceland, Reykjavik, Iceland,

Background: The aim of this study was to examine different definitions of renal recovery following postoperative acute kidney injury (AKI) and how these definitions associate with survival and the development and progression of chronic kidney disease (CKD).

Methods: This was a retrospective study of all patients who underwent abdominal, cardiothoracic, vascular, or orthopedic surgery at a single university hospital between 1998 and 2015. Recovery of renal function following postoperative AKI was assessed comparing 4 different definitions: serum creatinine (SCr) (i) < 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496611DOI Listing
January 2019
1 Read

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.

Am J Nephrol 2019 24;49(2):156-164. Epub 2019 Jan 24.

Humacyte Incorporated, Morrisville, North Carolina, USA,

Background: Chronic hemodialysis requires a mode of vascular access through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter (CVC). AVF is recommended over AVG or CVC due to increased patency and decreased intervention rates for those that mature. AVG are preferred over CVC due to decreased infection and mortality risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495355DOI Listing
January 2019
2 Reads

Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.

Am J Nephrol 2019 24;49(2):143-145. Epub 2019 Jan 24.

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496275DOI Listing
January 2019

Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort.

Am J Nephrol 2019 24;49(2):146-155. Epub 2019 Jan 24.

Division of Graduate Entry Medicine, School of Medicine, University of Nottingham, Nottingham, United Kingdom,

Background: Overt albuminuria (urinary albumin-creatinine ratio [ACR] > 300 mg/g) is an established risk factor for progression of nephropathy and total mortality. However, whether a reduction in ACR translates into a reduction in mortality and/or cardiovascular (CV) events among insulin-treated patients with type 2 diabetes (T2D) in routine practice is currently not known.

Methods: We obtained data on a large cohort of insulin users with T2D and nephropathy (baseline ACR ≥300 mg/g) from UK general practices between 2007 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496276DOI Listing
January 2019
7 Reads

Vancomycin-Associated Acute Kidney Injury in a Large Veteran Population.

Am J Nephrol 2019 24;49(2):133-142. Epub 2019 Jan 24.

Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee, USA,

Background: To determine the association of vancomycin with acute kidney injury (AKI) in relation to its serum concentration value and to examine the risk of AKI in patients treated with vancomycin when compared with a matched cohort of patients receiving non-glycopeptide antibiotics (linezolid/daptomycin).

Methods: From a cohort of > 3 million US veterans with baseline estimated glomerular filtration rate ≥60 mL/min/1.73 m2, we identified 33,527 patients who received either intravenous vancomycin (n = 22,057) or non-glycopeptide antibiotics (linezolid/daptomycin, n = 11,470). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496484DOI Listing
January 2019
2 Reads
2.669 Impact Factor

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.

Am J Nephrol 2019 22;49(2):125-132. Epub 2019 Jan 22.

Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA,

Background: Elevated serum concentrations of fibroblast growth factor 23 (FGF23) are associated with cardiovascular mortality in patients with chronic kidney disease and those undergoing dialysis.

Objectives: We tested the hypotheses that polymorphisms in FGF23, its co-receptor alpha-klotho (KL), and/or FGF23 receptors (FGFR) are associated with cardiovascular events and/or mortality.

Methods: We used 1,494 DNA samples collected at baseline from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial, in which patients were randomized to the calcimimetic cinacalcet or placebo for the treatment of secondary hyperparathyroidism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473180PMC
January 2019
3 Reads

Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease.

Am J Nephrol 2019 22;49(2):114-124. Epub 2019 Jan 22.

Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA.

Background: Chronic hypoxia is a well-recognized factor in the pathogenesis of chronic kidney disease (CKD). Loss of microcirculation is thought to lead to enhanced renal hypoxia, which in turn results in the development of fibrosis, a hallmark of progressive CKD. To evaluate the role of functional magnetic resonance imaging (MRI), we performed perfusion, oxygenation, and diffusion MRI measurements in individuals with diabetes and stage 3 CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387452PMC
January 2019
3 Reads
2.669 Impact Factor

Prediction of Chronic Kidney Disease Progression by Magnetic Resonance Imaging: Where Are We?

Am J Nephrol 2019 10;49(2):111-113. Epub 2019 Jan 10.

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496160DOI Listing
January 2019
1 Read

Comorbidity, Frailty, and Waitlist Mortality among Kidney Transplant Candidates of All Ages.

Am J Nephrol 2019 9;49(2):103-110. Epub 2019 Jan 9.

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA,

Background: Kidney transplantation (KT) candidates often present with multiple comorbidities. These patients also have a substantial burden of frailty, which is also associated with increased mortality. However, it is unknown if frailty is merely a surrogate for comorbidity, itself an independent domain of risk, or if frailty and comorbidity have differential effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374203PMC
January 2019
3 Reads

Cardiovascular Outcomes in African Americans with Sickle Cell Trait and Chronic Kidney Disease.

Am J Nephrol 2019 9;49(2):93-102. Epub 2019 Jan 9.

Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Background: Sickle cell trait (SCT) is common among African Americans and has been historically considered to be benign. Recently, SCT has been associated with an increased risk for chronic kidney disease (CKD) and cardiovascular disease in the general population. Our understanding of SCT has been extrapolated largely from data of patients with sickle cell disease (SCD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496058DOI Listing
January 2019
2 Reads

C4d in Native Glomerular Diseases.

Authors:
Preeti Chandra

Am J Nephrol 2019 4;49(1):81-92. Epub 2019 Jan 4.

Complement activation occurs in many glomerular diseases, the exact pathway(s) of activation has been studied in detail in some diseases but not in all. C4d is generated by the activation of classical and lectin pathways, and its presence can point to the activation of either of these pathways. This review aims to summarize the available data with regard to the deposition of glomerular C4d in native kidney biopsies in different glomerular pathologies that may be useful for future research into the role of complement activation in glomerular diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496059DOI Listing
January 2019
2 Reads

Effect of Bicarbonate-Buffered Dialysate on Ventricular Arrhythmias in Hemodialysis Patients.

Am J Nephrol 2019 2;49(1):74-80. Epub 2019 Jan 2.

Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA,

Background: The etiology of sudden cardiac death in patients with end-stage renal disease (ESRD) on hemodialysis (HD) is largely unknown, though there is evidence to suggest that metabolic alkalosis induced by HD with a high-bicarbonate dialysate/prescription may play a role.

Methods: We investigated the effects of metabolic alkalosis induced by HD with an acetate-containing bicarbonate-buffered dialysate on frequency of ventricular arrhythmia in 47 patients with ESRD on chronic HD using 48-h Holter monitoring in 3 phases: intra-HD, post-HD day 1, and post-HD day 2. Serum levels of bicarbonate, calcium, and potassium along with hemodynamics were measured pre-HD, post-HD, 20-h post-HD, and 44-h post-HD. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/495846
Publisher Site
http://dx.doi.org/10.1159/000495846DOI Listing
January 2019
13 Reads

Shortening the Duration of Corticosteroid Exposure in Minimal Change Disease: Can We Treat Adults Like Children?

Authors:
Andrew S Bomback

Am J Nephrol 2019 17;49(1):52-53. Epub 2018 Dec 17.

Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495351DOI Listing
December 2018
1 Read

Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease.

Am J Nephrol 2019 17;49(1):54-63. Epub 2018 Dec 17.

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan,

Background: In pediatric patients with steroid-sensitive nephrotic syndrome, recent trials have revealed that a 2-month, short-term steroid regimen is not inferior to an extended steroid course. However, the optimal duration of initial steroid therapy for adult steroid-sensitive minimal change disease (MCD) remains unclear.

Objectives: The aim of present study was to evaluate the effectiveness of a 2-month, short-term steroid regimen in the treatment of adult steroid-sensitive MCD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495352DOI Listing
December 2018
17 Reads

Sleep Duration and Proteinuria Progression: A Population-Based Cohort Study.

Am J Nephrol 2019 17;49(1):41-51. Epub 2018 Dec 17.

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan,

Background: Extensive studies have demonstrated that sleep is an important modulator of cardiovascular and metabolic diseases. However, its impact on renal function remains uncertain.

Methods: A total of 26,249 adults aged ≥20 years were recruited through voluntary health examinations in Taiwan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495847DOI Listing
December 2018
4 Reads